{ "company": "IQVIA Holdings", "ticker": "IQV", "period": { "from": "2026-03-20", "to": "2026-04-19", "days": 30 }, "sentiment_breakdown": { "positive": 22, "negative": 6, "neutral": 30 }, "synthesis": { "executive_summary": "Sentiment analysis for IQVIA Holdings (IQV) from 2026-03-20 to 2026-04-19. Analyzed 58 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "$1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics", "date": "2026-04-09", "source": "news", "score": 0.943 }, { "title": "Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F", "date": "2026-04-14", "source": "news", "score": 0.898 }, { "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "date": "2026-04-17", "source": "alpha_vantage", "score": 0.711 }, { "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "date": "2026-04-14", "source": "alpha_vantage", "score": 0.711 }, { "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "date": "2026-04-13", "source": "alpha_vantage", "score": 0.711 }, { "title": "Sumitomo Mitsui Trust Group Inc. Acquires 332,505 Shares of IQVIA Holdings Inc. $IQV", "date": "2026-04-14", "source": "alpha_vantage", "score": 0.67 }, { "title": "Charles River Labs stock: Margin Boost from Divestitures Signals Buy Opportunity", "date": "2026-04-10", "source": "alpha_vantage", "score": 0.67 }, { "title": "Patient Derived Xenograft (PDX) Models Market is estimated to Hit US$ 19.46 billion by 2032 | Major Companies - Charles River Laboratories, Champions Oncology, Inc., EPO Berlin-Buch GmbH", "date": "2026-04-09", "source": "alpha_vantage", "score": 0.527 }, { "title": "Whittier Trust Co. Has $4.04 Million Stake in IQVIA Holdings Inc. $IQV", "date": "2026-04-18", "source": "alpha_vantage", "score": 0.511 }, { "title": "Medpace Holdings Inc stock (US5840631062): Is its CRO execution strong enough to unlock new upside?", "date": "2026-04-15", "source": "alpha_vantage", "score": 0.511 } ], "top_negative": [ { "title": "100,000 child genomes power rare disease and cancer research", "date": "2026-04-14", "source": "alpha_vantage", "score": -0.66 }, { "title": "IQVIA Holdings (IQV) Traded Lower Due to AI-Related Fears Despite Reporting In-Line Results", "date": "2026-04-15", "source": "news", "score": -0.612 }, { "title": "IQVIA Holdings (IQV) Traded Lower Due to AI-Related Fears Despite Reporting In-Line Results", "date": "2026-04-15", "source": "alpha_vantage", "score": -0.612 }, { "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors", "date": "2026-04-16", "source": "alpha_vantage", "score": -0.2 }, { "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors", "date": "2026-04-09", "source": "alpha_vantage", "score": -0.2 }, { "title": "Board and pay up for vote as MFA Financial (NYSE: MFA) plans 2026 virtual meeting", "date": "2026-04-17", "source": "alpha_vantage", "score": -0.103 } ], "raw_data": { "total_items": 58, "items": [ { "source": "news", "source_name": "Yahoo Entertainment", "title": "IQVIA Holdings (IQV) Traded Lower Due to AI-Related Fears Despite Reporting In-Line Results", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_c44e19f9-3cbc-418d-9410-73cda22da63e", "date": "2026-04-15", "published_at": "2026-04-15T13:47:59Z", "sentiment": { "label": "negative", "score": -0.612, "confidence": 0.61 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "IQVIA Holdings Earnings Preview: What to Expect", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_7a015b60-c723-4986-abbb-957eeac0b01e", "date": "2026-04-15", "published_at": "2026-04-15T10:49:35Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F", "description": "The drug development services market presents significant opportunities due to the rise in R&D investments, AI adoption, personalized medicine, and emerging markets. Growth areas include preclinical research, regulatory optimization, and cloud-based data mana…", "url": "https://www.globenewswire.com/news-release/2026/04/14/3273662/28124/en/Drug-Development-Services-Market-Research-Report-2026-50-Bn-Opportunities-Trends-Competitive-Landscape-Strategies-and-Forecasts-2020-2025-2025-2030F-2035F.html", "date": "2026-04-14", "published_at": "2026-04-14T14:59:00Z", "sentiment": { "label": "positive", "score": 0.898, "confidence": 0.9 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "$1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics", "description": "The biopharmaceutical CXO market offers opportunities in strategic outsourcing, digital integration, resilient supply chains, and value-driven partnerships amidst evolving regulatory landscapes. The biopharmaceutical CXO market offers opportunities in strateg…", "url": "https://www.globenewswire.com/news-release/2026/04/09/3270735/28124/en/1-05-Bn-Biopharmaceutical-CXO-Markets-Global-Forecast-Report-2026-2032-How-Leading-Pharmas-Such-as-Pfizer-Roche-Novartis-Sanofi-and-AstraZeneca-Navigate-the-Evolving-Dynamics.html", "date": "2026-04-09", "published_at": "2026-04-09T10:05:00Z", "sentiment": { "label": "positive", "score": 0.943, "confidence": 0.94 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "IQVIA Holdings Inc. (IQV): Billionaire David Tepper Makes Minor Adjustment", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_aca927a4-f5a6-41e8-a121-330b5bf66fde", "date": "2026-04-07", "published_at": "2026-04-07T14:28:03Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Dermatomyositis Global Clinical Trials Market Review Report 2026: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status", "description": "The clinical trial report highlights opportunities in Dermatomyositis trials by revealing key trends in trial phases, sponsor types, and regions, particularly in G7 and E7 countries. It aids strategic decision-making by identifying prime trial locations and o…", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269299/28124/en/Dermatomyositis-Global-Clinical-Trials-Market-Review-Report-2026-Region-Country-G7-E7-Trial-Status-Trial-Phase-Sponsor-Type-and-End-Point-Status.html", "date": "2026-04-07", "published_at": "2026-04-07T13:28:00Z", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_14b688ee-99d8-45eb-830b-c9df2dca0d5d", "date": "2026-04-05", "published_at": "2026-04-05T18:31:21Z", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_0f826ad2-de99-47c1-afef-222a2c734ee3", "date": "2026-03-24", "published_at": "2026-03-24T14:43:11Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc stock (US46266C1053): Why Google Discover changes matter more now", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/iqvia-holdings-inc-stock-us46266c1053-why-google-discover-changes/69195633", "date": "2026-04-18", "summary": "Google's 2026 Discover Core Update is significantly changing how content about IQVIA Holdings Inc stock is delivered to mobile users, prioritizing personalized, visual feeds over traditional search rankings. This shift and its emphasis on frequent, timely, and visual content amplification can accelerate investor awareness and influence sentiment for IQVIA, a leader in clinical data and trials. The article explains how this update provides retail investors with an informational edge by quickly di", "sentiment_score": 0.416599, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc stock (US46266C1053): Why Google Discover changes matter more now", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-us46266c1053-why-google-discover-changes/69195633", "date": "2026-04-18", "summary": "The article discusses how Google's 2026 Discover Core Update significantly changes how information about IQVIA Holdings Inc. (IQV) stock is consumed. It emphasizes that Discover's personalized, visual feeds will increase investor awareness by proactively delivering tailored content on healthcare analytics and clinical trials to mobile users. This shift is highlighted as crucial for IQVIA's visibility, disseminating information faster, and influencing investor sentiment, particularly for retail i", "sentiment_score": 0.470568, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Whittier Trust Co. Has $4.04 Million Stake in IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-whittier-trust-co-has-404-million-stake-in-iqvia-holdings-inc-iqv-2026-04-18/", "date": "2026-04-18", "summary": "Whittier Trust Co. significantly reduced its stake in IQVIA Holdings Inc. by 54.6%, leaving them with 16,783 shares valued at approximately $4.04 million. Despite this, IQVIA reported strong Q4 results, exceeding revenue and EPS estimates, and issued positive guidance for FY2026. The company maintains a consensus \"Buy\" rating from analysts, with an average price target of $226.63.", "sentiment_score": 0.218917, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc stock (US46266C1053): Is real-world evidence now the real growth driver?", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-us46266c1053-is-real-world-evidence-now-the/69189609", "date": "2026-04-18", "summary": "IQVIA Holdings Inc. (US46266C1053) is positioned as a key player in the life sciences industry, leveraging real-world evidence and data analytics to accelerate drug development and commercialization. The company's integrated model, combining R&D solutions, real-world solutions, and technology, provides essential services to pharma giants and offers investors exposure to a resilient business model less dependent on individual drug pipelines. With strong analyst sentiment and a focus on AI integra", "sentiment_score": 0.489581, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Morgan Stanley Lifts Vertex Pharmaceuticals (VRTX) PT on Updated Biopharma Models", "url": "https://www.insidermonkey.com/blog/morgan-stanley-lifts-vertex-pharmaceuticals-vrtx-pt-on-updated-biopharma-models-1740603/", "date": "2026-04-18", "summary": "Morgan Stanley has raised its price target for Vertex Pharmaceuticals (VRTX) to $612 from $596, maintaining an Overweight rating. This decision follows updated biopharma models reflecting IQVIA trends and intra-quarter developments ahead of Q1 earnings. RBC Capital Markets also recently increased its price target for VRTX, citing a preview of Q1 biotech results and potential M&A activity balancing seasonal pressures.", "sentiment_score": 0.123007, "sentiment_label": "Neutral", "relevance_score": 0.646458, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "How New Real-World INGREZZA Data Versus AUSTEDO XR Will Impact Neurocrine Biosciences (NBIX) Investors", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/how-new-real-world-ingrezza-data-versus-austedo-xr-will-impa/amp", "date": "2026-04-17", "summary": "Neurocrine Biosciences reported new real-world data indicating that patients with tardive dyskinesia treated with INGREZZA demonstrated greater treatment persistence and fewer medication switches compared to those on AUSTEDO XR over six months. This analysis, using data from nearly 3,000 patients, could influence how healthcare providers and payers perceive INGREZZA as a first-line treatment. The article discusses how this data supports INGREZZA's market position, alongside the company's efforts", "sentiment_score": 0.143789, "sentiment_label": "Neutral", "relevance_score": 0.604734, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Board and pay up for vote as MFA Financial (NYSE: MFA) plans 2026 virtual meeting", "url": "https://www.stocktitan.net/sec-filings/MFA/def-14a-mfa-financial-inc-definitive-proxy-statement-b258983e5964.html", "date": "2026-04-17", "summary": "MFA Financial (NYSE: MFA) has announced its 2026 virtual annual meeting for June 3, 2026, where shareholders will vote on the election of two Class I directors, the ratification of KPMG LLP as the independent auditor, and an advisory Say-on-Pay resolution for executive compensation. The proxy statement details executive compensation for 2025, showing CEO Craig L. Knutson and President/CIO Bryan Wulfsohn received substantial salaries and incentive pay, with a significant portion of their compensa", "sentiment_score": 0.146628, "sentiment_label": "Neutral", "relevance_score": 0.627864, "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Banco Bilbao Vizcaya Argentaria SA Stock (BBVA) Moved Up by 3.77% on Apr 17: Facts Behind the Movement", "url": "https://www.tradingkey.com/news/market-movers/261796254-market-movers-bbva-20260417", "date": "2026-04-17", "summary": "Banco Bilbao Vizcaya Argentaria SA (BBVA) saw its stock price increase by 3.77% on April 17, despite initial selling pressure from analyst downgrades. The stock's rebound was driven by strong 2025 financial results, including record net profit and robust shareholder returns, alongside a supportive Spanish economic outlook and efforts by the European Central Bank. Technical indicators showed mixed signals, with a buy signal from MACD but neutral RSI and oversold Williams %R.", "sentiment_score": -0.347275, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.596783, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Parker-Hannifin Corp Stock (PH) Moved Up by 3.63% on Apr 17: Key Drivers Unveiled", "url": "https://www.tradingkey.com/news/market-movers/261796252-market-movers-ph-20260417", "date": "2026-04-17", "summary": "Parker-Hannifin Corp (PH) stock rose by 3.63% on April 17, driven by strong Q2 fiscal year 2026 earnings, increased full-year guidance, and positive analyst \"Moderate Buy\" ratings with upward price targets. The company is benefiting from broader industrial sector strength, including trends like onshoring and infrastructure investments, and anticipation of its upcoming Q3 earnings report on April 30, 2026. Despite positive momentum, risks include institutional selling, executive share sales, prem", "sentiment_score": -0.309969, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.683578, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-a0cf5a7a-3d9eaf639b86", "date": "2026-04-17", "summary": "IQVIA Holdings Inc. (IQV) saw its stock rise by 2.62% to $176.46 on Friday, outperforming the broader market during a positive trading session where the S&P 500 Index and Dow Jones Industrial Average also increased. Despite this gain, the company's stock closed 28.57% below its 52-week high of $247.05, achieved on January 9th.", "sentiment_score": 0.290851, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "US prescriptions for Lilly's Foundayo were 1,390 for week ended April 10 - IQVIA data shared by analyst shows", "url": "https://www.marketscreener.com/news/us-prescriptions-for-lilly-s-foundayo-were-1-390-for-week-ended-april-10-iqvia-data-shared-by-anal-ce7e50d2df8ff527", "date": "2026-04-17", "summary": "IQVIA data, as shared by an analyst, indicates that US prescriptions for Lilly's new drug Foundayo totaled 1,390 for the week ending April 10. This news follows earlier reports about Lilly's obesity pill also drawing 1,390 US prescriptions in its launch week, suggesting a strong initial uptake for the pharmaceutical company's new offerings.", "sentiment_score": 0.125372, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "alpha_vantage", "title": "GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?", "url": "https://www.tradingkey.com/analysis/stocks/us-stocks/261793997-openai-gpt-rosalind-cro-tradingkey", "date": "2026-04-17", "summary": "OpenAI's new life sciences LLM, GPT-Rosalind, has caused a slump in the Contract Research Organization (CRO) sector due to its potential to increase R&D efficiency, particularly impacting pre-clinical CROs. While clinical CROs like IQVIA are less vulnerable due to their high-touch services and data assets, investors are advised to differentiate between sub-sectors. The article also highlights the competitive landscape between OpenAI and Google in life sciences AI and suggests opportunities for C", "sentiment_score": -0.143989, "sentiment_label": "Neutral", "relevance_score": 0.931441, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings (IQV) Gets a Buy from RBC Capital", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IQV-N/pressreleases/1358432/iqvia-holdings-iqv-gets-a-buy-from-rbc-capital/", "date": "2026-04-17", "summary": "RBC Capital maintained a Buy rating on IQVIA Holdings (IQV) with a price target of $221.00, following a report from analyst Ryan Halsted. The company reported strong quarterly revenues of $4.36 billion and a net profit of $514 million for the quarter ending December 31. While Evercore ISI also issued a Buy rating, Citi assigned a Hold rating to IQVIA Holdings.", "sentiment_score": 0.001968, "sentiment_label": "Neutral", "relevance_score": 0.316107, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA stock falls as OpenAI unveils AI drug discovery model", "url": "https://m.investing.com/news/stock-market-news/iqvia-stock-falls-as-openai-unveils-ai-drug-discovery-model-93CH-4618987?ampMode=1", "date": "2026-04-16", "summary": "IQVIA Holdings shares dropped 2% after OpenAI announced GPT-Rosalind, a new AI model for accelerating drug discovery. This model aims to help researchers analyze large data volumes and convert scientific studies into healthcare applications, marking OpenAI's entry into the AI-driven scientific research field. Initial users include Amgen Inc., Moderna Inc., and the Allen Institute.", "sentiment_score": -0.40222, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA stock falls as OpenAI unveils AI drug discovery model", "url": "https://www.investing.com/news/stock-market-news/iqvia-stock-falls-as-openai-unveils-ai-drug-discovery-model-93CH-4618987", "date": "2026-04-16", "summary": "IQVIA Holdings (NYSE: IQV) shares fell 2% after OpenAI announced its entry into AI-driven drug discovery with GPT-Rosalind, a new model for life sciences research. The model aims to help researchers extract insights from data and convert scientific studies into healthcare applications. Initial users include Amgen, Moderna, and the Allen Institute, signaling OpenAI's push into applied AI for scientific breakthroughs.", "sentiment_score": -0.42561, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-thursday-when-compared-to-competitors-d7c86aec-3d54667572bf", "date": "2026-04-16", "summary": "IQVIA Holdings Inc. (IQV) stock fell by 3.45% on Thursday, closing at $171.95, despite an overall positive trading day for the broader market. This decline broke a three-day winning streak for the company's shares. The S&P 500 Index and the Dow Jones Industrial Average both saw gains on the same day.", "sentiment_score": -0.414997, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "KBC Group NV Boosts Stock Holdings in IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-kbc-group-nv-boosts-stock-holdings-in-iqvia-holdings-inc-iqv-2026-04-16/", "date": "2026-04-16", "summary": "KBC Group NV increased its stake in IQVIA Holdings Inc. by 68.2% in Q4, adding 315,883 shares to own a total of 779,128 shares valued at $175.62 million. Other institutional investors also showed significant interest in IQVIA, with Brighton Jones LLC boosting its position by 244.4% and Empowered Funds LLC by 102.1%. Analysts maintain a consensus \"Buy\" rating for IQVIA with an average target price of $226.63, following the company's Q4 earnings beat and strong revenue growth.", "sentiment_score": 0.417253, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "RBC Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $221", "url": "https://www.moomoo.com/news/post/68381059/rbc-capital-maintains-iqvia-holdings-iqvus-with-buy-rating-maintains", "date": "2026-04-16", "summary": "RBC Capital has reaffirmed its Buy rating on IQVIA Holdings (IQV.US) and maintained its price target at $221. This indicates continued confidence in the company's performance and future outlook from the analyst firm.", "sentiment_score": 0.424505, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA to Announce First-Quarter 2026 Results on May 5, 2026", "url": "https://www.biospace.com/press-releases/iqvia-to-announce-first-quarter-2026-results-on-may-5-2026", "date": "2026-04-16", "summary": "IQVIA Holdings Inc. (NYSE: IQV) will announce its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The company will also host a conference call and webcast at 9:00 a.m. Eastern Time on the same day for management to discuss the results. Interested parties can access the earnings release, financial information, and webcast details on the IQVIA Investor Relations website.", "sentiment_score": 0.131224, "sentiment_label": "Neutral", "relevance_score": 0.934862, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA to Announce First-Quarter 2026 Results on May 5, 2026", "url": "https://www.pharmiweb.com/press-release/2026-04-15/iqvia-to-announce-first-quarter-2026-results-on-may-5-2026", "date": "2026-04-15", "summary": "IQVIA Holdings Inc. will announce its first-quarter 2026 financial results before market open on Tuesday, May 5, 2026. The management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. Details for accessing the earnings release, webcast, and conference call registration are available on the IQVIA Investor Relations website.", "sentiment_score": 0.003469, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA will post quarterly results before the bell on May 5", "url": "https://www.stocktitan.net/news/IQV/iqvia-to-announce-first-quarter-2026-results-on-may-5-wqbw8qctvouz.html", "date": "2026-04-15", "summary": "IQVIA Holdings Inc. (NYSE: IQV) is scheduled to announce its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The company will also host a conference call and webcast at 9:00 a.m. Eastern Time on the same day to discuss the results. Interested parties can find the earnings release and webcast details on IQVIA's Investor Relations website.", "sentiment_score": 0.431778, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Massachusetts Financial Services Co. MA Buys 27,510 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-massachusetts-financial-services-co-ma-buys-27510-shares-of-iqvia-holdings-inc-iqv-2026-04-15/", "date": "2026-04-15", "summary": "Massachusetts Financial Services Co. increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 13.8%, purchasing an additional 27,510 shares to reach a total of 226,646 shares valued at $51.09 million. This move comes as IQVIA recently surpassed quarterly earnings and revenue estimates, reporting 10.3% year-over-year revenue growth. The company maintains an average \"Buy\" rating from Wall Street analysts with a target price of $226.63, and set its FY2026 EPS guidance between $12.55 and $12.85.", "sentiment_score": 0.433914, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Earnings Preview: What to Expect", "url": "https://www.inkl.com/news/iqvia-holdings-earnings-preview-what-to-expect", "date": "2026-04-15", "summary": "IQVIA Holdings (IQV) is expected to announce its FY2026 Q1 earnings soon, with analysts projecting a diluted profit of $2.51 per share, a 5.9% increase year-over-year. The company has a strong track record of exceeding consensus estimates and recently launched IQVIA.ai, an AI platform developed with NVIDIA, which has boosted investor confidence. Wall Street analysts maintain a \"Strong Buy\" rating for IQVIA, forecasting significant EPS growth and a substantial upside from current price levels.", "sentiment_score": 0.508619, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Assetmark Inc. Purchases 43,436 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-assetmark-inc-purchases-43436-shares-of-iqvia-holdings-inc-iqv-2026-04-15/", "date": "2026-04-15", "summary": "Assetmark Inc. significantly increased its stake in IQVIA Holdings Inc. by 33.6% in the fourth quarter, purchasing an additional 43,436 shares, bringing its total to 172,625 shares valued at $38.91 million. This increase makes Assetmark Inc. a 0.10% owner of IQVIA. Other institutional investors have also adjusted their holdings in IQVIA, which recently beat quarterly earnings expectations and received an average \"Buy\" rating from analysts with a target price of $226.63.", "sentiment_score": 0.302665, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings (IQV) Traded Lower Due to AI-Related Fears Despite Reporting In-Line Results", "url": "https://www.insidermonkey.com/blog/iqvia-holdings-iqv-traded-lower-due-to-ai-related-fears-despite-reporting-in-line-results-1738538/", "date": "2026-04-15", "summary": "IQVIA Holdings (IQV) shares traded lower despite reporting in-line results, attributed to AI-related fears, as noted by Oakmark Global Select Fund. Management believes the demand environment has stabilized and sees IQVIA as a net beneficiary of AI due to its proprietary data and expertise. The company was the top detractor for the Oakmark fund in Q1 2026, though the fund maintains a long-term positive outlook, expecting a recovery in client spending.", "sentiment_score": 0.016557, "sentiment_label": "Neutral", "relevance_score": 0.349905, "sentiment": { "label": "negative", "score": -0.612, "confidence": 0.61 } }, { "source": "alpha_vantage", "title": "Medpace Holdings Inc stock (US5840631062): Is its CRO execution strong enough to unlock new upside?", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/medpace-holdings-inc-stock-us5840631062-is-its-cro-execution-strong/69158542", "date": "2026-04-15", "summary": "Medpace Holdings Inc operates as a full-service Clinical Research Organization (CRO), providing comprehensive services for clinical trials with a focus on complex areas like oncology and rare diseases. The company's business model emphasizes recurring revenue from long-duration studies, proprietary technology, and a lean structure, positioning it as a key partner for biotech and pharmaceutical companies seeking efficient drug development. For investors, Medpace offers exposure to the stable heal", "sentiment_score": 0.248505, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.643767, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Earnings Preview: What to Expect", "url": "https://markets.chroniclejournal.com/chroniclejournal/article/barchart-2026-4-15-iqvia-holdings-earnings-preview-what-to-expect", "date": "2026-04-15", "summary": "IQVIA Holdings (IQV) is expected to announce its FY2026 Q1 earnings soon. Analysts anticipate a diluted EPS of $2.51, a 5.9% increase year over year, with the company historically exceeding consensus estimates in three out of the last four quarters. The company recently launched IQVIA.ai, an AI platform developed in collaboration with NVIDIA, which has been met with a positive investor response and a \"Strong Buy\" consensus rating from Wall Street analysts.", "sentiment_score": 0.049635, "sentiment_label": "Neutral", "relevance_score": 0.328425, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-39c60bc0-708c2bdc08e9", "date": "2026-04-14", "summary": "IQVIA Holdings Inc. (IQV) stock increased by 1.91% to $175.28 on Tuesday, outpacing the broader market which also saw gains with the S&P 500 Index rising 1.18% and the Dow Jones Industrial Average up 0.66%. This performance marked the second consecutive day of gains for IQVIA Holdings Inc.", "sentiment_score": 0.482393, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "100,000 child genomes power rare disease and cancer research", "url": "https://www.stocktitan.net/news/ILMN/illumina-and-the-center-for-data-driven-discovery-in-biomedicine-q0dgshhktb0n.html", "date": "2026-04-14", "summary": "Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) announced a partnership to analyze 100,000 whole genomes from pediatric patients for rare disease and cancer research. This cloud-based platform uses advanced software to enable real-time genomic discovery and will be accessible via the Kids First Data Resource Center, supporting ARPA-H's Pediatric Care eXpansion to link data across over 200 pediatric institutions. The initiative aims to accelerate research tra", "sentiment_score": -0.237226, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.630007, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Assessing IQVIA Holdings (IQV) Valuation After New AI Collaboration And Life Sciences Partnerships", "url": "https://www.sahmcapital.com/news/content/assessing-iqvia-holdings-iqv-valuation-after-new-ai-collaboration-and-life-sciences-partnerships-2026-04-13", "date": "2026-04-14", "summary": "IQVIA Holdings (IQV) is gaining attention due to new AI collaborations with NVIDIA and strategic life sciences partnerships, despite recent share price declines. The company's stock is currently assessed as undervalued by some metrics, with an estimated intrinsic discount, suggesting potential upside if future growth expectations are met. Investors are encouraged to review the company's financial data and risks, including potential pricing pressure and regulatory uncertainty.", "sentiment_score": 0.382375, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research", "url": "https://sg.finance.yahoo.com/news/labcorp-introduces-ai-powered-real-110000593.html", "date": "2026-04-14", "summary": "Labcorp has launched a new AI-powered real-world data platform, developed with Amazon Web Services (AWS) and Datavant, to accelerate Alzheimer's research and drug development. The platform utilizes de-identified healthcare data, including Labcorp's diagnostic and genomic datasets, combined with AI analytics to streamline data analysis, identify patient cohorts, and measure treatment effectiveness, ultimately aiming to shorten drug development timelines and improve patient outcomes. This innovati", "sentiment_score": 0.245518, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.605741, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. $IQV Stock Holdings Lessened by Running Oak Capital LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-iqvia-holdings-inc-iqv-stock-holdings-lessened-by-running-oak-capital-llc-2026-04-13/", "date": "2026-04-14", "summary": "Running Oak Capital LLC reduced its stake in IQVIA Holdings Inc. by 16.0% in Q4, selling 14,527 shares and now holding 76,219 shares valued at $17.18 million. Despite this, IQVIA remains 2.2% of Running Oak Capital's portfolio and its sixth-largest holding. Institutional investors collectively own 89.62% of IQVIA, with several major firms increasing or initiating positions. Analysts maintain a \"Buy\" rating for IQVIA with a consensus price target of $226.63, significantly higher than its current ", "sentiment_score": 0.275936, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hardman Johnston Global Advisors LLC Has $24.77 Million Holdings in IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-hardman-johnston-global-advisors-llc-has-2477-million-holdings-in-iqvia-holdings-inc-iqv-2026-04-13/", "date": "2026-04-14", "summary": "Hardman Johnston Global Advisors LLC decreased its stake in IQVIA Holdings Inc. by 8.2% in the fourth quarter, now holding 109,907 shares valued at $24.77 million. Despite this reduction, IQVIA reported strong Q4 earnings, beating analyst estimates with $3.42 EPS and $4.36 billion in revenue, and provided optimistic FY2026 guidance. Analysts currently have a consensus \"Buy\" rating for IQV with an average target price significantly above its current trading price.", "sentiment_score": 0.459367, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Sumitomo Mitsui Trust Group Inc. Acquires 332,505 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-sumitomo-mitsui-trust-group-inc-acquires-332505-shares-of-iqvia-holdings-inc-iqv-2026-04-13/", "date": "2026-04-14", "summary": "Sumitomo Mitsui Trust Group Inc. significantly increased its stake in IQVIA Holdings Inc. by 41.6%, purchasing 332,505 additional shares to own a total of 1,132,072 shares, valued at approximately $255.18 million. IQVIA recently exceeded quarterly earnings expectations with $3.42 EPS and 10.3% year-over-year revenue growth, and provided a strong FY2026 guidance. The company holds an overall \"Buy\" rating from analysts, though its current trading price of $167.49 is below its 200-day average.", "sentiment_score": 0.390182, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.67, "confidence": 0.67 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-a7a29e63-ac973e3e4ede", "date": "2026-04-13", "summary": "Shares of IQVIA Holdings Inc. (IQV) rose by 2.78% to $171.99 on Monday, outperforming the broader market. This strong performance ended a two-day losing streak for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw gains on what was a positive trading day.", "sentiment_score": 0.400701, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272337/0/en/ANI-Pharmaceuticals-Announces-the-Launch-of-Carbamazepine-Extended-Release-Capsules.html", "date": "2026-04-13", "summary": "ANI Pharmaceuticals has announced the launch of Carbamazepine Extended-Release Capsules in 100 mg, 200 mg, and 300 mg dosages. This generic version of Carbatrol® aims to strengthen the company's Generics portfolio and improve patient access to essential medicines. The U.S. annual sales for this product are estimated at approximately $65 million.", "sentiment_score": 0.108737, "sentiment_label": "Neutral", "relevance_score": 0.627451, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "ICON plc stock (IE0005711209): Is clinical trial demand strong enough to drive U.S. investor upside?", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/icon-plc-stock-ie0005711209-is-clinical-trial-demand-strong-enough-to/69137214", "date": "2026-04-13", "summary": "ICON plc, a leading contract research organization (CRO), plays a crucial role in drug development by managing clinical trials for pharmaceutical, biotech, and medical device companies globally, with significant U.S. operations. The company's business model offers stable revenue streams by outsourcing trial management, reducing costs and timelines for sponsors, and positioning it as an attractive investment for U.S. investors seeking exposure to the pharmaceutical market without direct biotech r", "sentiment_score": 0.226564, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.631826, "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley", "url": "https://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-price-target-raised-125847886.html", "date": "2026-04-11", "summary": "Morgan Stanley has increased its price target for Vertex Pharmaceuticals (VRTX) to $612 from $596, maintaining an Overweight rating on the shares. This adjustment reflects updated models based on IQVIA trends and intra-quarter updates in anticipation of Q1 earnings reports from biopharma companies.", "sentiment_score": 0.115121, "sentiment_label": "Neutral", "relevance_score": 0.60963, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Soars to Top Trading Volume With $240 Million Transaction Ahead of Earnings Release", "url": "https://www.bitget.com/amp/news/detail/12560605357862", "date": "2026-04-11", "summary": "IQVIA Holdings Inc. (IQV) experienced a significant trading volume of $240 million on April 10, 2026, despite a slight share price decrease, placing it at the top of daily trading volume rankings ahead of its earnings release on April 23, 2026. The company demonstrated strong Q4 2025 performance, surpassing revenue and EPS expectations, driven by AI initiatives and acquisitions, yet faces market challenges including economic pressures and competition. Technical analysis indicates a bearish trend", "sentiment_score": -0.218478, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Discipline and Rules-Based Execution in IQV Response", "url": "https://news.stocktradersdaily.com/news_release/90/Discipline_and_Rules-Based_Execution_in_IQV_Response_041026090001_1775869201.html", "date": "2026-04-10", "summary": "This article provides an AI-generated analysis of Iqvia Holdings Inc. (NYSE: IQV), indicating a neutral near and mid-term outlook with a potential long-term positive bias but elevated downside risk. It offers three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors.", "sentiment_score": 0.014682, "sentiment_label": "Neutral", "relevance_score": 0.312333, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Here’s Why Keeping IQV Stock in Your Portfolio Makes Sense Right Now", "url": "https://www.bitget.com/amp/news/detail/12560605356296", "date": "2026-04-10", "summary": "IQVIA Holdings (IQV) has shown strong share price growth, outperforming its industry, driven by its integration of AI into life sciences, commitment to sustainability, strategic acquisitions, and shareholder value initiatives. Despite these strengths, the company faces liquidity challenges with a declining current ratio. While IQV holds a \"Hold\" rank, alternative strong buy options like Dave Inc. (DAVE) and Maximus (MMS) are noted for investors.", "sentiment_score": 0.446084, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Here's Why You Should Retain IQV Stock in Your Portfolio Now", "url": "https://www.tradingview.com/news/zacks:d51e60dc9094b:0-here-s-why-you-should-retain-iqv-stock-in-your-portfolio-now/", "date": "2026-04-10", "summary": "IQVIA Holdings (IQV) has outperformed its industry over the past year and shows strong long-term EPS growth potential, driven by strategic AI integration (IQVIA.ai with NVIDIA), a commitment to sustainability, and proactive acquisitions. Despite these positive factors, the company faces significant challenges due to weak liquidity, as indicated by a consistently falling current ratio. IQVIA maintains a Zacks Rank of #3 (Hold), while other recommended stocks like Dave Inc. (DAVE) and Maximus (MMS", "sentiment_score": 0.630187, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "TOVX|Theriva Biologics Inc|Price:0.230|Chg%:-0.00", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tovx/stock-analysis", "date": "2026-04-10", "summary": "This article provides a comprehensive stock analysis of Theriva Biologics Inc (TOVX) from TradingKey, highlighting its healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It details the company's financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment, alongside technical indicators and a peer comparison. Analysts rate the stock as a \"Buy\" with a significant upside potential de", "sentiment_score": 0.121296, "sentiment_label": "Neutral", "relevance_score": 0.626659, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Soars to Top Trading Volume With $240 Million Transaction Ahead of Earnings Release", "url": "https://www.bitget.com/news/detail/12560605357862", "date": "2026-04-10", "summary": "IQVIA Holdings Inc (IQV) experienced strong investor interest with $240 million in trading volume, a 24.37% increase, despite a slight 0.97% share price decrease on April 10, 2026, ahead of its earnings announcement on April 23. This surge in volume pushed IQVIA to the top of daily trading rankings. The company has shown solid operational results, outperforming Q4 2025 analyst projections, but faces market caution due to broader economic pressures, integration challenges, and increased competiti", "sentiment_score": -0.258804, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Charles River Labs stock: Margin Boost from Divestitures Signals Buy Opportunity", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/charles-river-labs-stock-margin-boost-from-divestitures-signals-buy/69116787", "date": "2026-04-10", "summary": "Charles River Labs is strategically divesting low-margin units to focus on high-growth diagnostics, significantly boosting operating margins by at least 100 basis points and raising its 2026 EPS guidance. This pivot positions CRL as an attractive investment in the biopharma services sector, appealing to investors looking for resilient companies amid stabilizing demand and emphasizing profitability over top-line growth. Analysts maintain a \"Buy\" consensus, with a median price target of $202, sign", "sentiment_score": -0.123153, "sentiment_label": "Neutral", "relevance_score": 0.609222, "sentiment": { "label": "positive", "score": 0.67, "confidence": 0.67 } }, { "source": "alpha_vantage", "title": "Here’s Why Keeping IQV Stock in Your Portfolio Makes Sense Right Now", "url": "https://www.bitget.com/news/detail/12560605356296", "date": "2026-04-09", "summary": "IQVIA Holdings (IQV) has shown strong growth, with its share price increasing by 22.6% over the past year, driven by strategic AI integration, sustainability efforts, and key acquisitions. The company projects a long-term EPS growth rate of 13% and has an active share buyback program. However, IQVIA faces liquidity challenges with a declining current ratio, and currently holds a Zacks Rank of #3 (Hold), with alternative higher-ranked stock picks including Dave Inc. (DAVE) and Maximus (MMS).", "sentiment_score": 0.446912, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQV Technical Analysis & Stock Price Forecast", "url": "https://intellectia.ai/en/stock/IQV/technical", "date": "2026-04-09", "summary": "This article provides a technical analysis of IQVIA Holdings Inc (IQV), indicating a \"Strong Sell\" consensus based on various technical signals. It details momentum indicators like RSI and MACD, support and resistance levels, and analyzes its performance relative to several moving averages. The analysis concludes that IQV is currently exhibiting a \"Strong Sell\" sentiment, with its stock price at $168.98, trading below its 60-day and 200-day moving averages.", "sentiment_score": -0.400067, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc (IQV) Trading Down 3.39% on Apr 9", "url": "https://www.gurufocus.com/news/8785432/iqvia-holdings-inc-iqv-trading-down-339-on-apr-9?mobile=true", "date": "2026-04-09", "summary": "IQVIA Holdings Inc (IQV) shares dropped 3.39% on April 9th, trading at $166.69. Despite the intraday dip, analysts forecast an average target price of $234.30, suggesting a potential upside of 40.56%. GuruFocus estimates an even higher fair value of $264.33, indicating a 58.58% upside.", "sentiment_score": 0.077784, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-thursday-when-compared-to-competitors-5e6c463c-42c5bede7f14?mod=mw_quote_news", "date": "2026-04-09", "summary": "Shares of IQVIA Holdings Inc. (IQV) fell by 2.06% on Thursday, closing at $168.98, despite a positive trading session for the broader market with the S&P 500 and Dow Jones Industrial Average both rising. The company's stock is currently trading 31.60% below its 52-week high of $247.05, which was reached on January 9th.", "sentiment_score": -0.405371, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Patient Derived Xenograft (PDX) Models Market is estimated to Hit US$ 19.46 billion by 2032 | Major Companies - Charles River Laboratories, Champions Oncology, Inc., EPO Berlin-Buch GmbH", "url": "https://www.openpr.com/news/4461718/patient-derived-xenograft-pdx-models-market-is-estimated", "date": "2026-04-09", "summary": "The Patient Derived Xenograft (PDX) Models Market is projected to reach US$ 19.46 billion by 2032, growing at a CAGR of 15% from US$ 7.2 billion in 2025. This growth is driven by the increasing use of PDX models in preclinical research for drug efficacy testing, biomarker discovery, and personalized medicine in oncology. Key players in this market include Charles River Laboratories, Champions Oncology, Inc., and EPO Berlin-Buch GmbH, with significant recent developments in AI integration, expans", "sentiment_score": -0.149698, "sentiment_label": "Neutral", "relevance_score": 0.620401, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } } ] } }